$ITCI
Intra-Cellular Therapies, Inc.

2017 Q4 Form 10-Q Financial Statement

#000119312517337324 Filed on November 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q4
Revenue $5.055K $30.75K $97.90K
YoY Change -94.84% 605.04% 219.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.780M $5.320M $6.950M
YoY Change -16.83% -15.15% 6.27%
% of Gross Profit
Research & Development $26.93M $18.47M $21.18M
YoY Change 27.15% -22.77% -7.39%
% of Gross Profit
Depreciation & Amortization $50.00K $60.00K $50.00K
YoY Change 0.0% 20.0% 0.0%
% of Gross Profit
Operating Expenses $32.71M $23.79M $28.13M
YoY Change 16.28% -21.2% -4.32%
Operating Profit -$23.76M
YoY Change -21.29%
Interest Expense $1.440M $880.0K $780.0K
YoY Change 84.62% 7077.81% 44.44%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$31.27M -$22.87M -$27.25M
YoY Change 14.75% -22.28% -5.48%
Income Tax $40.00K -$4.016K $230.0K
% Of Pretax Income
Net Earnings -$30.21M -$22.87M -$27.49M
YoY Change 9.91% -24.43% -4.68%
Net Earnings / Revenue -597600.63% -74365.66% -28076.04%
Basic Earnings Per Share
Diluted Earnings Per Share -$554.3K -$526.7K -$635.3K
COMMON SHARES
Basic Shares Outstanding 54.58M shares 43.42M shares 43.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $464.3M $328.1M $384.1M
YoY Change 20.88% -38.99% -19.17%
Cash & Equivalents $37.79M $52.34M $48.64M
Short-Term Investments $426.5M $275.8M $335.5M
Other Short-Term Assets $4.900M $5.300M $4.000M
YoY Change 22.5% 32.5% -50.0%
Inventory
Prepaid Expenses
Receivables $0.00 $6.309K $94.34K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $469.2M $333.4M $388.2M
YoY Change 20.87% -38.46% -19.67%
LONG-TERM ASSETS
Property, Plant & Equipment $1.137M $679.6K $627.6K
YoY Change 81.19% 0.28% -19.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $75.77K $75.77K $75.77K
YoY Change 0.0% 0.0% 5.41%
Total Long-Term Assets $2.271M $755.4K $703.4K
YoY Change 222.92% 0.25% -17.0%
TOTAL ASSETS
Total Short-Term Assets $469.2M $333.4M $388.2M
Total Long-Term Assets $2.271M $755.4K $703.4K
Total Assets $471.5M $334.2M $388.9M
YoY Change 21.23% -38.41% -19.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.174M $4.408M $3.755M
YoY Change 64.42% -18.64% 129.94%
Accrued Expenses $8.000M $7.500M $6.800M
YoY Change 17.65% -27.18% 47.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.21M $11.88M $10.53M
YoY Change 34.91% -91.56% 68.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.800M $2.900M $2.900M
YoY Change -3.45% 11.54% 81.25%
Total Long-Term Liabilities $2.800M $2.876M $2.869M
YoY Change -2.39% 12.16% 79.61%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.21M $11.88M $10.53M
Total Long-Term Liabilities $2.800M $2.876M $2.869M
Total Liabilities $17.05M $14.75M $13.40M
YoY Change 27.23% -89.7% 70.48%
SHAREHOLDERS EQUITY
Retained Earnings -$407.2M -$377.0M -$309.5M
YoY Change 31.59% 33.71% 60.31%
Common Stock $862.5M $696.7M $685.3M
YoY Change 25.86% 2.23% 2.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $454.4M $319.4M $375.5M
YoY Change
Total Liabilities & Shareholders Equity $471.5M $334.2M $388.9M
YoY Change 21.23% -38.41% -19.67%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q4
OPERATING ACTIVITIES
Net Income -$30.21M -$22.87M -$27.49M
YoY Change 9.91% -24.43% -4.68%
Depreciation, Depletion And Amortization $50.00K $60.00K $50.00K
YoY Change 0.0% 20.0% 0.0%
Cash From Operating Activities -$24.79M -$14.41M -$28.45M
YoY Change -12.86% -51.42% -18.85%
INVESTING ACTIVITIES
Capital Expenditures -$510.0K -$110.0K $0.00
YoY Change 1000.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$151.4M $37.26M $1.680M
YoY Change -9109.52% -29.66% -100.67%
Cash From Investing Activities -$151.9M $37.17M $1.670M
YoY Change -9195.21% -29.83% -100.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 162.1M 0.000 -125.0M
YoY Change -229.74% -100.0% -39153.13%
NET CHANGE
Cash From Operating Activities -24.79M -14.41M -28.45M
Cash From Investing Activities -151.9M 37.17M 1.670M
Cash From Financing Activities 162.1M 0.000 -125.0M
Net Change In Cash -14.55M 22.76M -151.8M
YoY Change -90.41% -84.66% -46.88%
FREE CASH FLOW
Cash From Operating Activities -$24.79M -$14.41M -$28.45M
Capital Expenditures -$510.0K -$110.0K $0.00
Free Cash Flow -$24.28M -$14.30M -$28.45M
YoY Change -14.66% -51.77% -18.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4407655
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-219515
CY2017Q3 us-gaap Assets
Assets
334190841
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2017Q3 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
275781285
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
226000
CY2017Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
276001000
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54577626 shares
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200388020
CY2017Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3316378
CY2017Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4151120
CY2017Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2017Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
309787000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
333435470
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6309
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2634179
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
696695317
CY2017Q3 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
41300000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52340519
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43427344 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43427344 shares
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
4342
CY2017Q3 us-gaap Liabilities
Liabilities
14750765
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
334190841
CY2017Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2875612
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11875153
CY2017Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
21500000
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
75765
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5307357
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
679606
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3313785
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-377040068
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
18.97
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3610647 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2451396 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.69
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3610647 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.97
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
319440076
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47159303
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1448394
CY2016Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5329293
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
346182000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
388200116
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
94339
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2548769
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
685290815
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3754647
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-317239
CY2016Q4 us-gaap Assets
Assets
388903495
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
335458459
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
331000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
335776000
CY2016Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
25500000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48642225
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43292906 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43292906 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4329
CY2016Q4 us-gaap Liabilities
Liabilities
13400956
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
388903495
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2868622
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10532334
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
10700000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
75765
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4005093
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
627614
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3176383
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-309475366
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3101032 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.63
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
375502539
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Credit Risk</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Cash equivalents are held with major financial institutions in the United States. Certificates of deposit held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.</p> </div>
dei Amendment Flag
AmendmentFlag
false
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-401056
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
41000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3698294
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-67466978
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation
Depreciation
155262
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
Intra-Cellular Therapies, Inc.
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
dei Entity Central Index Key
EntityCentralIndexKey
0001567514
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17882679
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-67567118
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-88030
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
653169
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2416
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
653008
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
43632
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1302264
us-gaap Investment Income Interest
InvestmentIncomeInterest
2564747
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
143159
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
59166588
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-55699078
us-gaap Operating Expenses
OperatingExpenses
70372647
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
230784
us-gaap Net Income Loss
NetIncomeLoss
-67564702
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
230784
us-gaap Operating Income Loss
OperatingIncomeLoss
-70131865
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
97724
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
274674730
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
207254
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
334048572
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52489968
us-gaap Revenues
Revenues
240782
us-gaap Share Based Compensation
ShareBasedCompensation
11030572
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M25D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.904 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
128830 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.874 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y4M25D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
25.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
738195 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
99750 shares
dei Trading Symbol
TradingSymbol
ITCI
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43410072 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p> </div>
itci Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2
P9Y3M18D
itci Cash And Cash Equivalent Maximum Maturity Period
CashAndCashEquivalentMaximumMaturityPeriod
P3M
itci Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm
P3Y4M24D
itci Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm
P8Y6M
itci Available For Sale Securities Maturity Period
AvailableForSaleSecuritiesMaturityPeriod
More than three months
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-420275
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
153228717
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-88521941
us-gaap Depreciation
Depreciation
146784
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.06
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17806565
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-88108611
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-29351
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5641847
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
832618
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3784546
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
966704
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3997852
us-gaap Interest Expense
InterestExpense
12260
us-gaap Investment Income Interest
InvestmentIncomeInterest
2129927
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
171059
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
90585289
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-62806880
us-gaap Operating Expenses
OperatingExpenses
90459085
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
125450308
us-gaap Net Income Loss
NetIncomeLoss
-88941229
us-gaap Operating Income Loss
OperatingIncomeLoss
-90226278
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
419288
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
320098309
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48965
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
410732563
us-gaap Proceeds From Secured Lines Of Credit
ProceedsFromSecuredLinesOfCredit
125000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
450308
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
72652520
us-gaap Revenues
Revenues
232807
us-gaap Share Based Compensation
ShareBasedCompensation
10975931
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M25D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017 pure
CY2016Q3 us-gaap Interest Expense
InterestExpense
12260
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
763949
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
30188760
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.80 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43229087 shares
CY2016 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
25000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30496262
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6270528
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29432709
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
832618
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-30265327
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30184398
CY2016Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-230935
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23918232
CY2016Q3 us-gaap Revenues
Revenues
4362
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
3686746
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43253429 shares
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22774104
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5317577
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22874432
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4016
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
884763
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
23789949
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-22870416
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23759195
CY2017Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
96312
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18472372
CY2017Q3 us-gaap Revenues
Revenues
30754
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2500753
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43424387 shares

Files In Submission

Name View Source Status
0001193125-17-337324-index-headers.html Edgar Link pending
0001193125-17-337324-index.html Edgar Link pending
0001193125-17-337324.txt Edgar Link pending
0001193125-17-337324-xbrl.zip Edgar Link pending
d460592d10q.htm Edgar Link pending
d460592dex311.htm Edgar Link pending
d460592dex312.htm Edgar Link pending
d460592dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
itci-20170930.xml Edgar Link completed
itci-20170930.xsd Edgar Link pending
itci-20170930_cal.xml Edgar Link unprocessable
itci-20170930_def.xml Edgar Link unprocessable
itci-20170930_lab.xml Edgar Link unprocessable
itci-20170930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending